Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC lifted its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 98.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 830 shares of the biopharmaceutical company’s stock after purchasing an additional 411 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Insmed were worth $57,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of INSM. Vestal Point Capital LP raised its stake in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after purchasing an additional 850,000 shares during the last quarter. Victory Capital Management Inc. raised its position in Insmed by 209.9% in the third quarter. Victory Capital Management Inc. now owns 455,959 shares of the biopharmaceutical company’s stock worth $33,285,000 after acquiring an additional 308,819 shares in the last quarter. Westfield Capital Management Co. LP purchased a new position in Insmed in the third quarter worth $18,377,000. Eventide Asset Management LLC raised its position in Insmed by 34.2% in the third quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company’s stock worth $66,167,000 after acquiring an additional 231,210 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after acquiring an additional 214,130 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Wells Fargo & Company increased their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Morgan Stanley increased their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Royal Bank of Canada initiated coverage on Insmed in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price objective for the company. Finally, Stifel Nicolaus dropped their price target on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Insmed Stock Down 2.4 %

Shares of NASDAQ:INSM opened at $73.07 on Tuesday. The stock’s 50-day moving average price is $75.74 and its two-hundred day moving average price is $73.75. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The firm has a market cap of $13.23 billion, a price-to-earnings ratio of -13.07 and a beta of 1.28.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. On average, research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,996,328.94. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the sale, the insider now owns 102,766 shares in the company, valued at approximately $6,773,307.06. The trade was a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,859,028 in the last three months. 4.60% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.